Are there national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs? A survey of 33 European countries by unknown
RESEARCH Open Access
Are there national strategies, plans and
guidelines for the treatment of hepatitis C in
people who inject drugs? A survey of 33
European countries
Mojca Maticic1*, Jerneja Videcnik Zorman1, Sergeja Gregorcic1, Eberhard Schatz2, Jeffrey V Lazarus3
Abstract
Background: Hepatitis C virus (HCV) infection represents a major global health problem, which in high-income
countries now mostly affects people who inject drugs (PWID). Many studies show that the treatment of HCV
infection is as successful among PWID as among other populations and recently PWID have been included in the
international guidelines for the treatment of HCV infection. The aim of this survey was to collect data from
European countries on the existence of national strategies, action plans and clinical guidelines for HCV treatment in
the general population and PWID in particular.
Methods: Thirty-three European countries were invited to participate. Data on available national strategies, action
plans and guidelines for HCV treatment in the general population and in PWID specifically were collected
prospectively by means of a structured electronic questionnaire and analyzed accordingly.
Results: All of the 33 invited European countries participated in the survey. Twenty-two responses came from non-
governmental organizations, six from public health institutions, four from university institutions and one was an
independent consultant. Fourteen (42.4%) of the countries reported having a national strategy and/or national
action plan for HCV treatment, from which ten of them also reported having a national strategy and/or national
action plan for treatment of HCV infection in PWID. Nearly three-quarters reported having national HCV treatment
guidelines. PWID were included in the majority (66.7%) of the guidelines. Fourteen (42.4%) countries reported
having separate guidelines for the treatment of HCV infection in PWID.
Conclusions: Given the high burden of HCV-related morbidity and mortality in PWID in Europe, the management
of HCV infection should become a healthcare priority in all European countries, starting with developing or using
already-existing national strategies, action plans and guidelines for this population.
Introduction
Hepatitis C virus (HCV) imposes a considerable disease
burden worldwide and is one of the major underlying
causes of chronic liver disease-related death [1]. Approxi-
mately 50-80% of individuals exposed to HCV develop
chronic infection, and cirrhosis occurs in 10-15% of these
cases within the next 20 years [2,3]. The rate of progres-
sion to cirrhosis is highly variable and is influenced by
several factors [3]. Persons with cirrhosis are at increased
risk for developing end-stage liver disease and hepatocellu-
lar carcinoma, the sixth most common cause of cancer
globally [3,4]. Chronic HCV infection remains the leading
cause of liver transplantation; in 2004, one-quarter of liver
transplants performed in 25 European countries were
attributable to HCV [5,6].
It has been estimated that between 130 and 170 million
people are chronically infected with HCV worldwide and
that 350,000 deaths occur each year as a result of HCV
[7]. A 2009 analysis of data from 22 European countries
concluded that as many as nine million people in the
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focal area may be HCV-infected [4]. The World Health
Organisation (WHO) HCV prevalence estimates for 32
European countries indicated higher HCV prevalence in
southern and eastern Europe than in northern Europe
[8]. HCV was thought to cause an estimated 86,000
deaths annually in the entire European region [9].
After it became routine to screen blood products for
HCV in developed countries, intravenous drug use
replaced blood transfusion as the main HCV transmission
route in these countries [9,10]. Injecting drug use is a
major public health problem around the world as almost
16 million people injected drugs in 2007 [11]. According
to 2010 estimates, five million European people who inject
drugs (PWID) are HCV antibody-positive, with annual
incidence varying from 5% to 45% [11,12]. With 50% to
80% of PWID infected in the developed world, HCV is
much more prevalent than either hepatitis B virus infec-
tion or HIV in this high-risk population. Furthermore,
HCV sero-prevalence is much higher in PWID than in the
general population [13,14].
Research indicates that HCV treatment outcomes for
PWID are comparable to those for other patients in terms
of adherence to treatment, completion of the full treat-
ment course and attainment of a sustained viral response
(SVR) [15,16]. Moreover, modelling studies suggest that
treatment of active PWID could control the burden of
HCV in this population by decreasing the viral load
among current drug injectors and reducing transmission
rates [17]. Therefore, PWID should represent one of the
most important target populations for treatment. Since
the cohorts of non-treated PWID with chronic hepatitis C
are ageing they represent a significant proportion of
patients with advanced liver disease and liver-related mor-
tality [18,19]. Twenty to 25% of deaths among PWID are
related to the latter [20]. Further, daily use of cannabis
may be associated with advanced liver fibrosis, and heavy
alcohol consumption which is commonly present in
PWID is associated with a higher risk of cirrhosis [21,22].
However, many clinicians are reluctant to treat hepatitis C
in PWID because of concerns regarding re-infection, ser-
ious side-effects, potential lack of adherence to treatment,
high rates of concomitant alcohol abuse and mental health
issues [23].
National HCV treatment strategies, action plans and
clinical guidelines that recognise PWID as a distinct
patient population can help foster an enabling environ-
ment in which PWID are more likely to be given equal
access to treatment [24]. Little is known about the extent
to which these tools and resources are in place in Eur-
opean countries. The aim of our study was to collect data
from European countries on the existence of national
HCV treatment strategies, action plans and clinical guide-
lines for both the general population and PWID.
Methods
The study was performed between September and
December 2013. Data were collected by means of a
structured electronic questionnaire that was sent via
e-mail to individuals in 33 European countries. In the
survey Scotland was treated separately from the United
Kingdom and was presented as one of the participating
countries due to its well-recognised autonomous system
for the management of hepatitis C that is covered by
the Scottish National Healthcare System. The data from
the United Kingdom excluded the data for Scotland.
Informants were drawn from a database of contacts
maintained by the Hepatitis C Initiative of the Correla-
tion Network, and were selected because their work dee-
ply involves HCV/PWID issues.
The questionnaire was prepared at the Clinic for Infec-
tious Diseases and Febrile Illnesses, University Medical
Centre Ljubljana, Slovenia. It was constructed as a nine-
item survey in which answers could only be “yes” or “no”
(Table 1). Respondents were asked to provide references
for national guidelines on HCV treatment and had the
option of adding comments to clarify their answers. The
survey also requested the names, organisational affiliations
and countries of respondents. The questionnaire was writ-
ten in English since no language barriers were expected
from survey recipients.
PWID were defined as either people who were “actively”
injecting drugs, referring to those who had used drugs in
the past six months, or as people who were former injec-
tors, including those who were still active non-injection
drug users and/or used opioid substitution treatment
(OST). The definition was taken from recent recommen-
dations for the management of HCV infection in PWID
published by the International Network on Hepatitis in
Substance Users (INHSU) [25].
Data were collected by the Hepatitis C Initiative of the
Correlation Network and then were reviewed and analysed
by the authors of the questionnaire.
Results
Survey responses were obtained from all targeted coun-
tries. One survey was received from each of 31 countries.
For two other countries, Finland and Italy, two people sub-
mitted surveys. One respondent from Finland represented
a university-based institution and the other represented a
public health institution; both respondents from Italy
represented nongovernmental organisations (NGOs). The
two Finnish respondents provided the same answers, as
did the two Italian respondents. Each set of identical sub-
missions was combined into a single record for Finland
and a single record for Italy, with the two respondents
regarded as a single respondent. The Finland submission
counted as a university institution since more detailed
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comments were provided by the respondent from there.
Hence, the final dataset contained one record and one
respondent per country for 33 countries.
Respondents reported various affiliations. About two-
thirds of them (22; 66.7%) represented NGOs. Six
(18.2%) were based at public health institutions, four
(12.1%) were based at university institutions, and one
(3%) functioned as a freelance trainer and consultant.
The results of the survey are summarized in Table 2.
National strategy for treatment of HCV infection
Twelve countries (36.4%) reported having a national
HCV treatment strategy. All but one of them reported
that PWID are included in the strategy. The remaining
21 countries (63.6%) reported not having a national
HCV treatment strategy.
National action plan for treatment of HCV infection
Ten countries (30.3%) reported having a national action
plan for HCV treatment. In seven of the ten countries, this
plan was reported to include PWID. Respondents from
two additional countries, Croatia and Finland, indicated
that their countries were in the process of developing a
national strategy and action plan. The respondent from
Italy stated that his country was currently waiting for the
government to approve a national strategy and action
plan. The respondent from Austria did not answer this
question.
National guidelines for treatment of HCV infection
Twenty-four countries (72.7%) were said to have
national guidelines for treatment of HCV infection.
Among the nine countries that reported not having
national HCV treatment guidelines, some respondents
commented on guidance that was in the process of
being prepared. According to the respondent from
Romania, a non-governmental document that is well-
recognised and appreciated among clinicians provides
guidance on treatment decisions in that country. The
respondent from Finland reported that country’s
national guidelines to be under development. In Italy,
national guidelines reportedly had been prepared but
had not yet been approved by the government. Until
approval is granted, clinicians are expected to follow
regional guidelines since the national health service in
Italy is based on regional laws. In Switzerland, an aware-
ness campaign on HCV treatment exists for profes-
sionals on a national level; further, an analyses of the
situation regarding prevention and treatment of HCV
were being carried out by the federal authorities, with
the purpose of creating guidelines for HCV treatment in
the general population and PWID based on the results
of the analyses.
National guidelines for treatment of HCV infection in
people who inject drugs
Among the 24 countries reported to have national
guidelines for HCV treatment, 20 countries were said to
address HCV treatment for PWID in their guidelines.
Two additional countries, Serbia and Switzerland, had
contradictory information. In both cases, respondents
indicated that national guidelines for HCV treatment
did not exist, but that PWID were included in the
guidelines. Fourteen of the 33 countries (42.4%) were
reported to have separate guidelines for the treatment of
HCV in PWID; among them, 11 reported including
PWID in the national guidelines for HCV treatment.
A survey question asking if there are separate guidelines
for PWID who are on opiate substitution treatment (OST)
received 15 “yes” responses (45.5% of countries). Five
other countries had responses of “no,” and the question
was not answered by respondents from the remaining
countries. Nine countries (27.3%) were reported to have
separate guidelines for treatment of HCV infection in
active drug users. Among the remaining countries, respon-
dents from nine countries indicated that there were not
separate guidelines; no answer was provided in the other
cases.
Table 1 Survey questions
Does your country have a national strategy for treatment of HCV? yes/no
If yes, does it include actions with regards to PWID? yes/no
Does your country have a national action plan for treatment of HCV (in place of or in addition to a strategy)? yes/no
If yes, does it include actions in regard of PWID? yes/no
Does your country have national guidelines for treatment of HCV? yes/no
If yes, does this include guidelines in regard of PWID or are these separate guidelines in regard of PWID:
Guidelines in regard of PWID are included yes/no
Separate guidelines in regard of PWID yes/no
In case there are separate guidelines in regard of PWID, are they applicable to:
PWID on opiate substitution treatment yes/no
Active PWID yes/no
HCV: hepatitis C virus. PWID: people who inject drugs.
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N/N Y/N Y Y N Y N
Austria
NGO
Y/Y na/na Y na na na na
Belgium [26]
NGO




Y/Y Y/Y Y Y N na na
Bulgaria
Public health
N/na Y/N Y na Y na na
Croatia
NGO
N/na N/na Y Y na na na
Czech Republic [28-30]
University
N/N N/N Y N Y Y Y
Denmark [31,32]
Public health
Y/Y Y/Y Y Y Y na Y
Estonia [33]
NGO
N/N N/N N N N N N
Finland [34]
NGO
N/N N/N N N N N N
France [35,36]
NGO
Y/Y Y/Y Y Y N na na
Germany [37,38]
NGO
N/N N/N Y Y N na na
Greece [39]
Public health
Y/Y Y/Y Y Y Y Y N
Hungary [40]
NGO
N/N N/N Y Y Y Y Y
Ireland [41]
NGO
Y/Y Y/N Y N Y Y na
Italy [42,43]
NGO
N/N N/N N N N N N
Latvia [44]
NGO
Y/N N/N Y Y Y Y N
Lithuania [45]
University
Y/Y N/N Y Y Y Y Y
Macedonia
NGO
N/N N/na Y Y Y Y Y
Montenegro
NGO
N/N N/N N N N N N
Norway
NGO
Y/Y N/N Y Y Y na Y
Poland [46]
NGO
N/N N/N Y Y N Y na
Portugal
NGO
N/N N/N Y Y N na na
Romania [47]
NGO
N/N N/N N na na Y na
Scotland [48]
Public health
Y/Y Y/Y Y Y Y Y Y
Serbia
NGO
N/N N/N N Y na na Y
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Discussion
During the last two decades, it appears that low HCV
treatment uptake among PWID in developed countries
has contributed to high levels of advanced liver disease
and liver disease-related mortality, with 20-25% of deaths
in this population attributable to liver disease [59-61]. In
general, not accessing HCV treatment has been associated
with several barriers arising mostly from poor knowledge
and inaccurate perceptions about HCV [62].
Seven respondents involved in this survey (Denmark,
France, Greece, Ireland, Scotland, Slovenia and the United
Kingdom excluding Scotland) reported having both a
national strategy and a national action plan for treatment of
HCV infection that also include actions in regard of PWID.
They also reported on having national guidelines for treat-
ment of HCV infection and separate guidelines for treat-
ment of HCV-infected PWID. In all of these countries,
apart from Denmark, there have been several studies on
HCV treatment access in PWID. The proportion of treated
PWID reached 40% in a French study and 57% in a Greek
study [63,64]. In Slovenia, the proportion of PWID treated
for HCV increased from 3% to 13% in the first three years
after the 2007 introduction of the national strategy, action
plan and clinical guidelines; 72% of all the newly treated
patients in the period 2008-2010 reported a history of drug
use [64]. As for Scotland, the clinical services that were
developed with the implementation of the Hepatitis C
Action Plan led to a doubling in the number of those who
initiated therapy in the years 2010–2011 compared to the
period before the 2006 introduction of the plan. Eighty per-
cent of people initiating HCV treatment in 2010–2011 had
a history of injecting drugs [65]. These observations sup-
port the premise that the national policy context is a crucial
factor in determining how much PWID will be able to ben-
efit from HCV treatment interventions. To systematically
address the barriers to treatment, several steps could be
undertaken, with three essential steps being the establish-
ment of a national strategy, action plan and clinical guide-
lines on HCV treatment.
Although ever/current drug injectors have treatment effi-
cacy and safety outcomes that are comparable to those for
people with no history of drug use [15,66-70], and success-
ful treatment could reduce the likelihood of HCV transmis-
sion among PWID by eliminating potential sources of
infection [9], international and national treatment guide-
lines historically have excluded PWID, particularly current
injectors, from being treated for hepatitis C [15,70,71]. In
2011, however, the Clinical Practice Guidelines of the Eur-
opean Association for the Study of the Liver (EASL) were
revised to endorse the provision of HCV treatment to cer-
tain PWID based on an individual approach [72]. The 2014
update to these guidelines goes even further in terms of
considering substance users as a treatable patient group at
risk provided they wish to receive treatment and are willing
and able to maintain follow-up visits [62].
It is well recognised that the extremely varied political,
economic and social circumstances of different European
countries lead to very different health needs and health
outcomes at the national level [73]. Furthermore, HCV
infection shows great diversity among European countries,
not only in its prevalence in the general population and
among PWID [8,12], but also in the treatment of hepatitis
C. Treatment funding, availability of anti-HCV drugs and
the settings for HCV treatment in PWID vary immensely
among the European countries. Policies, strategies and
guidelines for HCV management therefore must be tai-
lored to the specific national or sub-national context [73].
Several studies have shown that compared to other well-
accepted medical interventions, HCV treatment is cost-
effective [7]. According to the 2013 Global Policy Report
Table 2 Survey results (Continued)
Slovakia [49]
NGO
N/N N/N Y Y Y na na
Slovenia [50,51]
University
Y/Y Y/Y Y Y Y Y Y
Spain [52]
Public health
N/N N/N Y Y N Y N
Sweden
NGO
N/N N/N N N N N N
Switzerland
Public health
N/N N/N N Y na Y na
The Netherlands [53-55]
NGO




Y/Y Y/Y Y Y N na na
*If respondents provided references to national guidelines, the citations are given in brackets following country names. All respondent affiliations are indicated in
italics following country names.
N: no. Y: yes. na: no answer. NGO: non-governmental organization. HCV: hepatitis C virus. PWID: people who inject drugs. OST: opioid substitution treatment.
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on the Prevention and Control of Viral Hepatitis in WHO
Member States, publicly funded treatment for HCV
is available in 34 out of 44 Member States from the
European Region that responded [73]. Among the partici-
pating Member States that were also included in our
study, all, except Switzerland, have publicly funded HCV
treatment; the data for Albania and Slovakia were not
available. Norway, Portugal, Romania, Greece and Scot-
land, which were included in our study, did not participate
in the WHO survey. Among 25 countries of our survey
that also provided WHO data on funding, 14 of them
reported to have treatment guidelines that include PWID,
whereas only eight countries reported on having a national
strategy.
Interestingly, in Latvia, which reported having a national
strategy and treatment guidelines that include PWID, only
75% of the total treatment cost is publicly funded [73]. In
Finland, which according to our survey is in the process of
developing a national strategy and action plan for HCV
treatment, active injecting drug use is an absolute contra-
indication for publicly funded HCV treatment [73].
According to the results of our study, only 27% of the
respondents reported having separate guidelines for HCV
treatment in active drug users; however, this treatment is
publicly funded [73]. Switzerland provides no public fund-
ing as well as no national strategy and guidelines. As for
Scotland, which is regarded globally as a model of good
practice, the government made a serious financial invest-
ment to support the 2006 launch and subsequent imple-
mentation of the Hepatitis C Action Plan, with a special
focus on PWID [74].
According to the 2013 WHO Global Policy Report,
only 38.6% of Member States in the European region
reported having boceprevir and telaprevir on national
essential medicine lists or subsidised by governments
[73]. It is of special concern that even pegylated inter-
feron was reported not to be present in 20.5% of coun-
tries, or ribavirin in 13.6% of countries. In the last year,
HCV treatment success and safety have advanced tre-
mendously thanks to new treatment options. Unfortu-
nately, the extremely high prices of the new direct
acting antivirals (DDAs) will limit their availability in
many European countries [75,76]. Therefore, national
strategies and action plans might turn out to be crucial
in promoting access to the new drugs. However, it is
worth mentioning that no studies of DAAs have been
performed in PWID populations thus far. Even the stu-
dies of boceprevir and telaprevir have excluded PWID
other than OST patients, which means that no efficacy
and safety data exist for this population [62].
Beside the treatment of HCV, medical health interven-
tions for PWID also include various programmes for the
management of drug addiction, including OST, which has
been shown to facilitate HCV treatment and reduce HCV
acquisition among PWID [15]. It is of special concern that
some European countries are reluctant to use OST [77].
However, almost half of the countries involved in this
study reported on having separate guidelines for HCV
treatment in PWID on OST. Already existing settings
for the management of drug use and for the treatment
of HCV infection in PWID vary immensely among the
European countries. Therefore, various models have been
proposed for HCV treatment in PWID to be performed
inter-disciplinarily in either community-based clinics, drug
treatment settings, viral hepatitis clinics/hospitals or being
integrated into the primary/secondary/tertiary medical set-
ting [78]. The EASL Clinical Practice Guidelines also call
for the treatment of HCV in PWID to be undertaken
using a multidisciplinary approach [62]. Countries should
decide on the most appropriate model for their local facil-
ities. Slovenia provides an example of a multidisciplinary
model of good practice that was introduced through a
national strategy, action plan and clinical guidelines. The
Slovenian model called for the integration of 18 existing
drug treatment centres and five viral hepatitis centres into
a national healthcare network for HCV treatment in
PWID [50].
There are some limitations to our study. The infor-
mants who participated in the survey were selected from
the database of the Correlation Network’s Hepatitis C
Initiative, and all of them were deeply involved in the
field of PWID/HCV infection, most as representatives of
non-governmental organizations. In all but two countries,
only one person was approached to participate in the sur-
vey. The validity of the data was not checked separately.
The data capture method of the study allows a potential
bias since the organizations with strong motivations, but
not necessarily linked to government policy input, can
have a differing view and/or experiences to what is a cur-
rent official policy. Therefore, an exploration of civil
society versus political leaders/government replies from
European countries on the existence of national strate-
gies, action plans and clinical guidelines for HCV treat-
ment in the general population and PWID in particular
might be a matter for further research.
Conclusions
To the best of our knowledge this is the first study to
present data on the existence of national strategies,
action plans and guidelines on HCV treatment in 33
European countries, and to present data of this nature
relating specifically to PWID.
The results of the survey provide data on how Eur-
opean countries address the problem of HCV treatment
in PWID and try to achieve hepatitis C policy objectives
with regards to treatment. The survey results highlight
major gaps that should be addressed in order to
improve hepatitis C treatment at the national level,
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particularly among PWID. Given the burden of HCV-
related morbidity and mortality in this at-risk popula-
tion, the management of HCV infection in PWID
should become a healthcare priority in all European
countries. Our data demonstrate some awareness of the
threat that HCV poses to PWID in Europe and indicate
that decision-makers in some countries are willing to
consider this subgroup of HCV patients for treatment.
With several new direct acting antivirals on the horizon,
there is hope that HCV infection can be cured in the
majority of patients in the nearest future. However, the
most highly potent regimens may remain under-utilised
until the group at greatest risk for HCV infection is
recognized as urgently needing access to this treatment.
Competing interests
The authors declare that they have no competing interests regarding this
manuscript.
Authors’ contributions
MM carried out the conceptualisation, design, and coordination of the study,
drafted the manuscript and prepared the final manuscript. JVZ and SG
performed the study analysis and assisted with drafting the manuscript. ES
prepared the database of respondents and carried out the collection of data.
JVL provided considerable input during the drafting and finalization of the
manuscript. All authors read and approved the final manuscript.
Declarations
This article has been published as part of BMC Infectious Diseases Volume 14
Supplement 6, 2014: Viral Hepatitis in Europe. The full contents of the
supplement are available online at http://www.biomedcentral.com/
bmcinfectdis/supplements/14/S6. The publication charges for this
supplement were funded by AbbVie as an unrestricted grant to
Rigshospitalet, the University of Copenhagen. AbbVie further funded the
printing of the supplement with additional financial support from the Drug
Prevention and Information Programme (DPIP) of the European Union.
Authors’ details
1Clinic for Infectious Diseases and Febrile Illnesses, University Medical Centre
Ljubljana, Ljubljana, Slovenia. 2Correlation Network, Foundation De
Regenbook Groep, Amsterdam, The Netherlands. 3CHIP, Centre for Health
and Infectious Disease Research and WHO Collaborating Centre on HIV and
Viral Hepatitis, Rigshospitalet, University of Copenhagen, Copenhagen,
Denmark.
Published: 19 September 2014
References
1. Lozano R, Naghavi M, Foreman K, et al: Global and regional mortality from
235 causes of death for 20 age groups in 1990 and 2010: a systematic
analysis for the Global Burden of Disease Study 2010. Lancet 2012,
380:2095-2128.
2. Kamal SM: Acute hepatitis C: a systematic review. Am J Gastroenterol 2008,
103:1283-1297.
3. Chen SL, Morgan TR: The Natural History of Hepatitis C Virus (HCV)
Infection. Int J Med Sci 2006, 3:47-52.
4. van Meer S, de Man RA, Siersema PD, Erpecum KJ: Surveillance for
hepatocellular carcinoma in chronic liver disease: Evidence and
controversies. World J Gastroenterol 2013, 19:6744-6756.
5. Mühlberger N, Schwarzer R, Lettmeier B, Sroczynski G, Zeuzem S, Siebert U:
HCV-related burden of disease in Europe: a systematic assesement of
incidence, prevalence, morbidity and mortality. BMC Public Health 2009,
22:34-42.
6. Terrault N: Liver transplantation in the setting of chronic HCV. Best Pract
Res Clin Gastroenterol 2012, 26:531-548.
7. Lavanchy D: The global burden of hepatitis C. Liver Int 2009, 29:74-81.
8. World Health Organization: Hepatitis C – global prevalence (update). Wkly
Epidemiol Rec 2000, 75:18-19.
9. Hatzakis A, Wait S, Bruix J, Buti M, Carballo M, Cavaleri M, Colombo M,
Delarocque-Astagneau E, Dusheiko G, Esmat G, Esteban R, Goldberg D,
Gore C, Lok AS, Manns M, Marcellin P, Papatheodoridis G, Petrle A, Prati D,
Piorkowsky N, Rizzetto M, Roudot-Thoraval F, Soriano V, Thomas HC,
Thursz M, Valla D, van Damme P, Veldhuijzen IK, Wedemeyer H, Wiesing L:
The state of hepatitis B and C in Europe: report from the hepatitis B and
C summit conference. J Viral Hepat 2011, 18(Suppl 1):1-16.
10. Esteban JI, Sauleda S, Quer J: The changing epidemiology of hepatitis C
virus infection in Europe. J Hepatol 2008, 48:148-162.
11. Degenhardt L, Hall L: Extent of illict drug use and dependence, and their
contribution to the global burden of disease. Lancet 2012, 379:55-70.
12. Mehta SH, Astemborski J, Kirk GD, Strathdee SA, Nelson KE, Vlahov D,
Thomas DL: Changes in blood-borne infection risk among injection drug
users. J Infect Dis 2011, 203:587-594.
13. Wiessing L, Guarita B, Giraudon I, Brummer-Korvenkontio H, Salminen M,
Cowan SA: European monitoring of notifications of hepatitis C in the
general population and among injecting drug users – the need to
improve quality and comparability. Eurosurveillance 2008, 13:1-5.
14. Hagan H, Snyder N, Hough E, Yu T, McKeirnan S, Boase J, Duchin J: Case-
reporting of acute hepatitis B and C among injection drug users. J Urban
Health 2002, 79:579-585.
15. Hellard M, Sacks-Davis R, Gold J: Hepatitis C treatment for injection drug
users: a review of the available evidence. Clin Infect Dis 2009, 49:561-573.
16. Dalgaard O: Follow up studies of treatment for hepatitis C virus infection
among injection drug users. Clin Infect Dis 2005, 40:336-338.
17. Martin NK, Vickerman P, Foster GR, Hutchinson SJ, Goldberg DJ, Hickman M:
Can antiviral therapy for hepatitis C reduce the prevalence of HCV
among injecting drug user populations? A modeling analysis of its
prevention utility. J Hepatol 2011, 54:1137-1144.
18. Grebely J, Raffa JD, Lai C, Kerr T, Fischer B, Krajden M, Tyndall MF: Impact of
hepatitis C virus infection on all-cause and liver-related mortality in a
large community-based cohort of inner city residents. J Viral Hepat 2011,
18:32-41.
19. Darke S, Kaye S, Duflou J: Comparative cardiac pathology among deaths
due to cocaine toxicity, opioid toxicity and non-drug-related causes.
Addiction 2006, 101:1771-1777.
20. McDonald SA, Hutchinson SJ, Bird SM, Mills PR, Dillon J, Bloor M,
Robertson C, Donaghy M, Hayes P, Graham L, Goldberg DJ: A population-
based record linkage study of mortality in hepatitis C-diagnosed
persons with or without HIV coinfection in Scotland. Stat Methods Med
Res 2009, 18:271-283.
21. Hezode C, Roudot-Thoraval F, Nguyen S, Grenard P, Julien B, Zafrani ES,
Pawlotsky JM, Dhumeaux D, Lotersztajn S, Mallat A: Daily cannabis
smoking as a risk factor for progression of fibrosis in chronic hepatitis C.
Hepatology 2005, 42:63-71.
22. Ostapowicz G, Watson KJ, Locarnini SA, Desmond PV: Role of alcohol in
the progression of liver disease caused by hepatitis C virus infection.
Hepatology 1998, 27:1730-1735.
23. Edlin BR, Seal KH, Lorvick J, Kral AH, Ciccarone DH, Moore LD, Lo B: Is it
justifiable to withhold treatment for hepatitis C from illict-drug users?
N Engl J Med 2001, 345:211-215.
24. Papatheodoridis GV, Tsochatzis E, Hardtke S, Wedemeyer H: Barriers to care
and treatment for patients with chronic viral hepatitis in Europe: a
systematic review. Liver International 2014, doi: 10.1111/liv.12565.
25. Robaeys G, Grebely J, Mauss S, Bruggmann P, Moussalli J, De Gottardi A,
Swan T, Arain A, Kautz A, Stöver H, Wedemeyer H, Schaefer M, Taylor L,
Backmund M, Dalgard O, Prins M, Dore GJ, International Network on
Hepatitis in Substance Users: Recommendations for the management of
hepatitis C virus infection among people who inject drugs. Clin Infect Dis
2013, 57(Suppl 2):129-137.
26. Gerkens S, Natasha M, Thiry N, Hulstaert F: KCE Reports 173B Type Health
Technology Assesment (HTA)., https://kce.fgov.be/fr/node/1370.
27. Husic-Selimovic A, Vukobrat-Bijedic Z, Bevanda M, Mesihovic R, Zerem E,
Ahmetagic S, Trbojevic S, Verhaz A, Kezic Z, Zildzic M, Bojanic J, Petrovic J,
Stojic V, Ferhatovic M, Ibrahimpasic N, Mrdjen V, Zivlak N, Barac T, Bebek-
Ivankovic H, Calkic L, Karin M, Dobrovoljski A, Rajic R, Skrbic M, Babic N,
Bevanda-Glibo D: Diagnosis and treatment of chronic viral hepatitis B
and C: doctrinal approach. Med Arh 2012, 66(Suppl 1):56-68.
Maticic et al. BMC Infectious Diseases 2014, 14(Suppl 6):S14
http://www.biomedcentral.com/1471-2334/14/S6/S14
Page 7 of 9




29. Health promotion for young prisoners. [www.adiktologie.cz/en/articles/
detail/414/4008/Health-promotion-for-young-prisoners-HPYP-].
30. Štefunkova M: Mortality and health status of former injecting drug users




31. National handlingsplan til forebyggelse af hepatitis C. [http://www.sst.dk/
publ/Publ2007/CFF/Stofmisbrugere/Forebyggelse_hepC_stofmisbrugere.pdf].
32. Vejledning om HIV og hepatitis B og V virus. [http://www.sst.dk/publ/
Publ2013/03mar/HIVogHepBogCvejl.pdf].
33. Ministry of social affairs. [http://www.sm.ee].
34. National institute for health and welfare. [http://www.thl.fi].
35. French National Authority of Health. [http://www.has-sante.fr].
36. French Ministry of Social Affairs and Health. [http://www.sante.gouv.fr].
37. Backmund M: Leitlinien der Deutschen Gesellschaftfür Suchtmedizin
(DGS e.V.): Therapie der chronischen Hepatitis C beiintravenös
Drogengebrauchern. Suchtmed 2006, 8:129-133[http://www.
dgsuchtmedizin.de/uploads/media/Leitlinien_Hepatitis_C.pdf].
38. Hepatitis-C_virus (HCV)-infektion; prophylaxe, diagnostic und therapie.
[http://www.awmf.org/leitlinien/detail/ll/021-012.html].
39. Hellenic center for disease control and prevention. [http://www.keelpno.gr].
40. MEGHÍVÓ - Krónikus vírushepatitisek kivizsgálási és kezelési protokollja.
[http://www.informed.hu/informed_site-ok/majbeteg/alapitvany/meghivo-
kronikus-virushepatitisek-kivizsgalasi-es-kezelesi-protokollja-185078.html].
41. Health service executive. National hepatitis C strategy 2011-2014. [http://
www.hse.ie/eng/services/Publications/HealthProtection/HepCstrategy.pdf].
42. Epatite C, a chepunto siamo?. [http://www.infermieri24.it/
approfondimento/show/124/epatite-punto-siamo.html].
43. Gruppodi lavoro epatiti. [http://www.salute.gov.it/portale/temi/p2_6.jsp?
lingua=italiano&id=3275&area=Malattie%20infettive&menu=vuoto].
44. Viksna L, Rozentale B, Kuse V: MEGHÍVÓ - Krónikus vírushepatitisek
kivizsgálási és kezelési protokollja. [http://www.vmnvd.gov.lv/uploads/files/
4d08c09c5b481.pdf].
45. Lietuvos Respublikos Sveikatos Apsaugos Ministras Isakymas. Del letinio
virusinio C hepatitio diagnostikos ir ambulatorinio gydymo
kompensuojamaisiais vaistais tvarkos apraso tvirtinimo. [http://www.vlk.lt/
veikla/veiklos-sritys/kompensuojamieji-vaistai/Documents/
SAMv960_RedNr_2.pdf].
46. Halota W, Flisiak R, Boron-Kaczmarska A: Standardy leczenia wirusowych
zapalen watroby typu C Rekomendacje Polskiej Grupy Ekspertów HCV
2011.[http://www.choroby-zakazne.pl/uploads/REKOMENDACJE%20PGE-HCV
%202011-1.pdf].
47. Carta Alba a hepatitei C in Romania. [http://www.aluzii.ro/wp-content/
uploads/2013/03/CARTA-ALBA-A-HEPATITEI-C-IN-ROMANIA.pdf].
48. Scotish intercollegiate Guidelines Network. Management of hepatitis C:
a national clinical guideline. [http://www.sign.ac.uk/pdf/sign133.pdf].
49. Glasa J, Skladaný Ľ, Holomáň J: Method Statement on Rational Therapy.
[http://www.health.gov.sk/?metodicke-listy-racionalnej-farmakoterapie].
50. Maticic M, Kastelic A: National guidelines for the management of
hepatitis C virus infection in drug users in Slovenia. Zdrav Vestn 2009,
78:529-539.
51. Maticic M, Brinovec V, Lesnicar G, Vidmar L, Meglic-Volkar J: Hepatitis C v
Sloveniji. ISIS 1999, 8:49-51.
52. Generalitat de Catalunya, Departament de Salut. Criteris de indicacio del





53. Rihtlijnbehandeling van chronischen hepatitis C virusinfectie. [http://
www.mdl.nl/uploads/240/474/7019_krt_mdl_hepatitis_c_12.pdf].
54. Croes E, van der Poel A: ImplemenatioevoorstelvooreenDoorbrakkproject
opsporing en behandeling van hepatitis C in de verslavingszorg. [http://
www.trimbos.nl/~/media/Themas/3_Preventie/Infectieziekten/Doorbraak%
20Opsporing%20en%20behandeling%20HCV%20in%20verslavingszorg.ashx].
55. Netherlands institute of mental health and addiction. Doorbraakproject
hepatitis C in de verslavingszorg. [http://www.trimbos.nl/~/media/
Themas/3_Preventie/Infectieziekten/Factsheet%20Doorbraak%20Hepatitis%
20C.ashx].
56. Department of health. Hepatitis strategy for England. [http://www.nhs.uk/
hepatitisc/SiteCollectionDocuments/pdf/hepatitis-c-strategy-for-england.pdf].
57. Department for health. Hepatitis action plan for England. [http://www.
nhs.uk/hepatitisc/SiteCollectionDocuments/pdf/hepatitis-c-action-plan-for-
england.pdf].
58. National institute for health and care excellence. PH43 Hepatitis B and C –
ways to promote and offer testing:guidance. [http://www.nice.org.uk/
Search.do?x=0&y=0&searchText=hepatitis&newsearch=true&page=1#/
search/?reload].
59. Mehta SH, Genberg BL, Astemborski J, Kavasery R, Kirk GD, Vlahov D,
Strathdee SA, Thomas DL: Limited uptake of hepatitis C treatment among
injection drug users. J Community Health 2008, 33:126-133.
60. Grebely J, Raffa JD, Ali C, Krajden M, Kerr T, Fischer B, Tyndall MW: Low
uptake of treatment for hepatitis C virus infection in a large community-
based study of inner city residents. J Viral Hep 2009, 16:352-358.
61. Moreno C, Deltenre P, Pawlotsky JM, Henrion J, Adler M, Mathurin P:
Shortened treatment duration in treatment-naive genotype 1 HCV patient
with rapid virological response: a meta-analysis. J Hepatol 2010, 52:25-31.
62. European Association for the study of the liver: EASL clinical practice
guidelines: management of hepatitis C virus infection. J Hepatol 2014,
60:392-420.
63. Lazarus JV, Sperle I, Maticic M, Wiessing L: A systematic review of hepatitis
C virus treatment access in people who inject drugs in the European
region and the availability of medicine to treat them. BMC Infectious
Diseases 2014.
64. Maticic M, SelicKurincic T, Kastelic A, Poljak M, Lesnicar G, Meglic-Volkar J,
Rajter M, Prah J, Baklan Z, Ciglaric M, Pancur M: A national
multidisciplinary healthcare network for treatment of hepatitis C in
people who inject drugs in Slovenia: high enrollement, adherence and
sustained virological response [Abstract]. Suchtmed 2013, 15:245.
65. Hutchinson S, Goldberg D, Brown G, Rowan N, Dillon J, Taylor A, Ahmed S:
Hepatitis C strategy in Scotland. Viral Hepatitis in Practice 2012, 4(2):1-4.
66. Lindenburg CE, Lambers FA, Urbanus AT, Schinkel J, Jansen PL, Krol A,
Castleen G, van Santen G, van der Berg CH, Coutinho RA, Prins M,
Weeking CJ: Hepatitis C testing and treatment among active drug users
in Amsterdam: results from the DUTCH-C project. Eur J Gastroenterol
Hepatol 2011, 23:23-31.
67. Dore GJ, Hellard M, Matthews GV, Grebely J, Haber PS, Petoumenos K,
Yeung B, Marks P, van Beek I, McCaughan G, White P, French R,
Rawlinson W, Lloyd AR, Kaldor JM: Effective treatment of injecting drug
users with recently acquired hepatitis C virus infection. Gastroenterology
2010, 138:123-135.
68. Waizmann M, Ackermann G: High rates of sustained virological response
in hepatitis C virus-infected injection drug users receiving directly
observed therapy with peginterferon alpha-2a (40KD) (PEGASYS) and
once daily ribavirin. J Subst Abuse Treat 2010, 38:338-345.
69. Melin P, Chousterman M, Fontanges T, Ouzan D, Rotily M, Lang JP,
Marcellin P, Cacoub P: Effectiveness of chronic hepatitis C treatment in
drug users in routine clinical practice: results of a prospective cohort
study. Eur J GastroenterolHepatol 2010, 22:1050-1057.
70. Aspinall E, Corson S, Doyle J, Grebely J, Hutchinson SJ, Dore GJ,
Goldberg DJ, Hellard ME: Peginterferon and ribavirin treatment for
chronic hepatitis C virus in people who inject drugs: a systematic review
and meta-analysis. Clin Infect Dis 2013, 57(Suppl 2):80-89.
71. European Association for the study of the liver: EASL international
consensus conference on Hepatitis C. Paris, 26-28, February 1999,
consensus statement. J Hepatol 1999, 30:956-961.
72. European Association for the study of the liver: EASL clinical practice
guidelines: management of hepatitis C virus infection. J Hepatol 2011,
55:245-264.
73. World Health Organisation. Global policy report on the prevention and
control of viral hepatitis. [http://www.who.int/topics/hepatitis].
74. Morris K: Tackling hepatitis C: a tale of two countries. Lancet 2011,
377:1227-1228.
75. Maasoumy B, Manns MP: Optimal treatment with boceprevir for chronic
HCV infection. Liver Int 2013, 33(Suppl 1):14-22.
Maticic et al. BMC Infectious Diseases 2014, 14(Suppl 6):S14
http://www.biomedcentral.com/1471-2334/14/S6/S14
Page 8 of 9
76. Hill A, Khool S, Fortunak J, Simmons B, Ford N: Minimum costs for
producing Hepatitis C Direct Acting Antivirals, for use in large-scale
treatment access programs in developing countries. Clin Infect Dis 2014.
77. Bruggmann P, Litwin AH: Models of care for the management of
hepatitis C virus among people who inject drugs: one size does not fit
all. Clin Infect Dis 2013, 57(Suppl 2):56-61.
78. Selin J, Hakkarainen P, Partanen A, Tammi T, Tigerstedt C: From political
controversy to a technical problem? Fifteen years of opioid substitution
treatment in Finland. Int J Drug Policy 2013, 24:66-72.
doi:10.1186/1471-2334-14-S6-S14
Cite this article as: Maticic et al.: Are there national strategies, plans and
guidelines for the treatment of hepatitis C in people who inject drugs?
A survey of 33 European countries. BMC Infectious Diseases 2014
14(Suppl 6):S14.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Maticic et al. BMC Infectious Diseases 2014, 14(Suppl 6):S14
http://www.biomedcentral.com/1471-2334/14/S6/S14
Page 9 of 9
